The antiviral drug remdesivir is confirmed to be effective against Covid-19. Three studies presented during the Conference on Retroviruses and Opportunistic Infections (Croi) held in Denver (USA) showed how it can reduce some symptoms of long-Covid and also mortality in immunocompromised people hospitalized for Covid.
“The real-world data presented at the Croi conference continues to reinforce remdesivir’s robust efficacy and safety profile as well as the drug’s potential benefits in people with Covid-19,” said Frank Duff, senior vice president, Virology Therapeutic Area head of Gilead Sciences – As we enter the fourth year of Covid-19, remdesivir remains the standard of antiviral care for people hospitalized with Covid-19.”
In detail, a first study has shown on over 50 thousand patients that the use of remdesivir is associated with a 10% reduced risk of post-Covid conditions. From a second analysis conducted on approximately 15 thousand immunocompromised people hospitalized for Covid, it emerged that treatment with remdesivir reduces 28-day mortality by 25%.
A third real-world study compared over 33 thousand patients who had received both remdesivir and dexamethasone with the same number who had received only dexamethasone monotherapy. In this case, patients also treated with the antiviral had a 20% lower mortality if they did not receive oxygen, 26-29% if they also treated with oxygen and 19% lower if they were supported with ventilation invasive mechanics or with ECMO.
breaking latest news © Copyright ANSA